2-Phenyl-5-(3,4,5-trimethoxy-phenyl)-oxazole-4-carboxylic acid amide | 89205-24-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Phenyl-5-(3,4,5-trimethoxy-phenyl)-oxazole-4-carboxylic acid amide
• 英文别名: 2-Phenyl-5-(3,4,5-trimethoxyphenyl)-1,3-oxazole-4-carboxamide
• CAS: 89205-24-3
• 化学式: C₁₉H₁₈N₂O₅
• 分子量: 354.362
• InChiKey: AHLPYPYPMMOUDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  α-(3,4,5-Trimethoxyphenyl)acyl amino acid methyl ester hydrochloride 在 ammonium hydroxide 、 碳酸氢钠 、 乙酸乙酯 、 三氯氧磷 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-Phenyl-5-(3,4,5-trimethoxy-phenyl)-oxazole-4-carboxylic acid amide
  参考文献：
  名称：

  Syntheses of 5-substituted oxazole-4-carboxylic acid derivatives with inhibitory activity on blood platelet aggregation.

  摘要：

  α-异氰基乙酸甲酯在碱存在下与酰化试剂反应，合成了 5-取代的噁唑-4-羧酸甲酯。噁唑甲酯被转化成羧酸和羧酰胺。然后，通过噁唑-4-羧酰氯制备出 N-烷基噁唑-4-羧酰胺。此外，还通过 N-酰基-α-苯甲酰基甘氨酸甲酯的环化合成了 2-取代的噁唑，这些噁唑甲酯是通过α-苯甲酰基甘氨酸甲酯的酰化，然后对生成的噁唑甲酯进行氨解而得到的。对这些噁唑化合物进行了体外和体内血小板聚集抑制活性评估。其中一些化合物的抑制活性与阿司匹林相当。其中，5-(3, 4, 5-三甲氧基苯基) 恶唑-4-甲酰胺是体内外试验中活性最强的化合物。

  DOI：

  10.1248/cpb.31.4417

文献信息

• OXAZOLE TYROSINE KINASE INHIBITORS
  申请人：Sareum Limited

  公开号：US20130102592A1

  公开（公告）日：2013-04-25

  The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar 1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted en by one or more substituents R 1 ; Ar 2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R 2 ; and R 1 and R 2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

  本发明提供了一种化合物，其为公式（1）的酰胺或其盐、溶剂合物、N-氧化物或互变异构体；其中：a为0或1；b为0或1：前提是a和b的和为0或1；T为O或NH；Ar1为含有最多4个来自O、N和S的杂原子的单环或双环5-至10-成员芳基或杂芳基基团，并且可以被一个或多个取代基R1取代；Ar2为含有最多4个来自O、N和S的杂原子的单环或双环5-至10-成员芳基或杂芳基基团，并且可以被一个或多个取代基R2取代；R1和R2如权利要求所定义。该化合物是激酶抑制剂，特别是FLT3、FLT4和Aurora激酶的抑制剂。
• KCC2 expression enhancing compounds and uses thereof
  申请人：Whitehead Institute for Biomedical Research

  公开号：US11331313B2

  公开（公告）日：2022-05-17

  Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome (RTT), a severe neurodevelopmental disorder caused by mutations in the X-linked gene Methyl CpG binding Protein 2 (MECP2), has been linked to deficits in KCC2. The disclosure reports the use of CRISPR/Cas9 genome-editing technology to generate stem cell-derived, genetically defined KCC2 reporter human neurons for large-scale compound screening. This screening platform has been utilized to identify a number of small molecule compounds that are capable of enhancing KCC2 expression in both wild-type and RTT neurons, as well as organotypical brain slices cultured from wild-type mice. These first-in class compounds may be applied as a novel therapeutic approach to restore the impaired balance between excitation and inhibition observed in neurological diseases, psychiatric disorders, and central nervous system injuries.

  氯化钾共转运体-2（KCC2）在大脑功能中起着至关重要的作用，KCC2的缺乏与神经系统疾病、精神疾病和中枢神经系统损伤有关。特别是雷特综合征（RTT），这是一种由 X 连锁基因甲基 CpG 结合蛋白 2（MECP2）突变引起的严重神经发育障碍，与 KCC2 的缺陷有关。该披露报告了使用 CRISPR/Cas9 基因组编辑技术生成干细胞衍生的、基因定义的 KCC2 报告人神经元，用于大规模化合物筛选。利用这一筛选平台鉴定出了许多小分子化合物，这些化合物能够增强野生型和 RTT 神经元以及从野生型小鼠培养的器官型脑片中的 KCC2 表达。这些首创化合物可作为一种新型治疗方法，用于恢复在神经系统疾病、精神疾病和中枢神经系统损伤中观察到的受损的兴奋和抑制之间的平衡。
• US20140275041A1
  申请人：——

  公开号：US20140275041A1

  公开（公告）日：2014-09-18
• KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF
  申请人：Whitehead Institute for Biomedical Research

  公开号：US20200085817A1

  公开（公告）日：2020-03-19

  Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome (RTT), a severe neurodevelopmental disorder caused by mutations in the X-linked gene Methyl CpG binding Protein 2 (MECP2), has been linked to deficits in KCC2. The disclosure reports the use of CRISPR/Cas9 genome-editing technology to generate stem cell-derived, genetically defined KCC2 reporter human neurons for large-scale compound screening. This screening platform has been utilized to identify a number of small molecule compounds that are capable of enhancing KCC2 expression in both wild-type and RTT neurons, as well as organotypical brain slices cultured from wild-type mice. These first-in class compounds may be applied as a novel therapeutic approach to restore the impaired balance between excitation and inhibition observed in neurological diseases, psychiatric disorders, and central nervous system injuries.
• US8378095B2
  申请人：——

  公开号：US8378095B2

  公开（公告）日：2013-02-19